Dr. Marilyn McLaughlin

Claim this profile

York Hospital

Studies Breast Cancer
Studies Mixed-Cell Lymphoma
4 reported clinical trials
25 drugs studied

Area of expertise

1Breast Cancer
Marilyn McLaughlin has run 2 trials for Breast Cancer. Some of their research focus areas include:
HER2
lymph node
breast
2Mixed-Cell Lymphoma
Marilyn McLaughlin has run 1 trial for Mixed-Cell Lymphoma. Some of their research focus areas include:
Stage III
Stage IV

Affiliated Hospitals

Image of trial facility.
York Hospital
Image of trial facility.
York Hospital Oncology & Infusion Care In Wells

Clinical Trials Marilyn McLaughlin is currently running

Image of trial facility.

Targeted Therapy

for Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
Recruiting1 award Phase 29 criteria
Image of trial facility.

Imlunestrant

for Early Breast Cancer

This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.
Recruiting2 awards Phase 36 criteria

More about Marilyn McLaughlin

Clinical Trial Related9 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Marilyn McLaughlin has experience with
  • Abemaciclib
  • Afatinib
  • Atezolizumab And PHESGO
  • Atezolizumab And Talazoparib
  • Crizotinib
  • Entrectinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Marilyn McLaughlin specialize in?
Is Marilyn McLaughlin currently recruiting for clinical trials?
Are there any treatments that Marilyn McLaughlin has studied deeply?
What is the best way to schedule an appointment with Marilyn McLaughlin?
What is the office address of Marilyn McLaughlin?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security